dm+d

Unassigned

New Medicines

Prevention of hereditary angioedema - monthly injection

Information

New molecular entity
CSL Behring
CSL Behring

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Factor XIIa-inhibitory monoclonal antibody reduces oedema during angioedema episode. Given by sc injection every four weeks for 12 weeks after an IV loading dose
The incidence of hereditary angioedema is approximately 1 in 50,000 although there may be variation geographically. It can affect people of any ethnic group or gender [2].
Prevention of hereditary angioedema - monthly injection
Intravenous and
Subcutaneous injection